Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Neoplasm Metastasis 1Multiple Sclerosis, Chronic Progressive 1Multiple Sclerosis 1Multiple Myeloma 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Natalizumab × Clear all
NCT01416181 2017-09-11

ASCEND in SPMS

Biogen

Phase 3 Terminated
889 enrolled 31 charts

Multiple Sclerosis, Neoplasm Metastasis, Multiple Sclerosis, Chronic Progressive

NCT00675428 2014-09-19

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Biogen

Phase 1/2 Terminated
6 enrolled 6 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡